AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma

  • Histologic confirmation of the original primary tumor via pathology report required

• Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 10 mm by CT scan, MRI, or caliper measurement by clinical exam OR ≥ 20 mm by chest x-ray

  • Lymph nodes must be ≥ 15 mm in short axis when measured by CT scan or MRI

• Has ≥ 1 "target lesion" to be used to assess response, as defined by RECIST criteria

  • Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days following completion of radiotherapy

• Must have received 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease

  • Initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation therapy, non-cytotoxic agents, or extended therapy administered after surgical or non-surgical assessment
  • Must have a platinum-free interval of < 12 months, progressed during platinum-based therapy, or have persistent disease after platinum-based therapy
  • One additional cytotoxic regimen for management of recurrent or persistent disease allowed
• Ineligible for a higher priority GOG protocol, if one exists (e.g., any active GOG phase III protocol for the same patient population)

PATIENT CHARACTERISTICS:

• GOG performance status (PS) 0-2 (for patients who received 1 prior regimen)
• GOG PS 0-1 (for patients who received 2 prior regimens)
• ANC ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• SGOT ≤ 3.0 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• PTT ≤ 1.5 times ULN
• INR ≤ 1.5 times ULN
• Proteinuria ≤ 1+ by urinalysis OR ≤ 1 g/24 hrs by 24-hour urine collection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No neuropathy (sensory or motor) > grade 1
• No peripheral edema or lymphedema > grade 2
• No active bleeding diathesis

• No thromboembolic or ischemic event within the past 12 months, including any of the following:

  • Deep venous thrombosis
  • Pulmonary embolism
  • Transient ischemic attack
  • Cerebral infarction
  • Myocardial infarction
• No serious or non-healing wound
• No known HIV or hepatitis C positivity or chronic or active hepatitis B

• No active infection requiring antibiotics

  • Uncomplicated urinary tract infection allowed
• No other concurrent serious infection or nonmalignant medical illness that is uncontrolled or whose control may be jeopardized by study treatment
• No psychiatric condition or other condition that would preclude giving informed consent or meeting study requirements

• No history of primary endometrial cancer unless all of the following criteria are met:

  • No greater than stage IB disease
  • No more than superficial myometrial invasion
  • No vascular or lymphatic invasion
  • No poorly differentiated subtypes, including papillary serious, clear cell, or other FIGO grade 3 lesions
• No other invasive malignancies within the past 3 years except for nonmelanoma skin cancer or localized cancer of the breast, head and neck, or skin

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior surgery, radiotherapy, or chemotherapy
• No prior cancer treatment that would contraindicate study treatment
• No prior fully human anti-HGF monoclonal antibody AMG 102 or other HGF/c-met pathway inhibitors

• No prior non-cytotoxic therapy for management of recurrent or persistent disease

  • Prior biologic (non-cytotoxic) therapy as part of primary treatment regimen allowed

• No prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the past 3 years

  • Prior radiotherapy for localized cancer of the breast, head and neck, or skin is allowed provided it was completed > 3 years ago and the patient remains free of recurrent or metastatic disease

• No prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the past 3 years

  • Prior adjuvant chemotherapy for localized breast cancer allowed provided it was completed > 3 years ago and the patient remains free of recurrent or metastatic disease

• More than 30 days since prior surgery (14 days for minor surgical procedures)

  • Central venous catheter placement allowed at any time point before study enrollment provided the patient has recovered and any surgical wound has healed
• At least 1 week since prior hormonal therapy directed at the malignant tumor
• At least 3 weeks since any other prior therapy directed at the malignant tumor, including immunologic agents

• More than 7 days since prior and no concurrent therapeutic anti-coagulation therapy with warfarin, heparin, or low molecular weight heparin

  • Low-dose warfarin (≤ 2 mg orally daily) for prophylaxis against central venous catheter thrombosis allowed